Background: The birth prevalence of congenital heart defects (CHDs) has decreased in Canada and Europe. Recommended intake of folic acid in pregnancy is a suggestive risk-reducing factor for CHDs. We investigated the association between periconceptional intake of folic acid supplements and infant risk of CHDs. Conclusions: Periconceptional folic acid supplement use showed no association with severe CHDs in the newborn. An unexpected association with an increased risk of septal defects warrants further investigation.
Introduction
Congenital heart defects (CHDs) are among the most common birth defects and represent an important cause of infant morbidity and mortality, affecting 5-13 per 1000 births worldwide. [1] [2] [3] After decades of increasing prevalence of CHDs believed to be explained by improved diagnostics and reporting, 4, 5 several studies have shown a changing time trend with decreasing prevalence in Canada and Europe after 1999, 6, 7 and also in Norway from 2005. 3 This decline in CHDs has been partly explained by the concurrent introduction of folic acid food fortification or the increasing use of periconceptional folic acid supplements. Folic acid is the synthetic form of folate, which is necessary in DNA, RNA, and protein synthesis, and therefore important during fetal development. Periconceptional intake of folic acid has been shown to reduce the risk for neural tube defects, 8, 9 and women worldwide have been recommended to take folic acid supplements before conception and in the beginning of pregnancy. More than 70 countries have also implemented folic acid fortification of grain products, 5, 6 whereas health authorities in Norway have refrained from such fortification and recommended periconceptional use of folic acid supplements. 10 A possible protective effect of folic acid supplements on CHDs is, however, controversial. While some studies have reported reduced risk of CHDs in children whose mothers have taken multivitamins with folic acid 11, 12 or pure folic acid supplements, 13, 14 or after folic acid food fortification, 6 other studies have reported no effect on CHDs of folic acid food fortification. 15, 16 In the Medical Birth Registry of Norway, information on the use of folic acid and multivitamin supplements has been recorded for all women giving birth since 1999. 17 We have taken advantage of Norway's national health registries and the Cardiovascular Disease in Norway project (CVDNOR) to investigate infant risk of specific types of CHDs among mothers using folic acid supplements in the periconceptional period.
Methods

Data sources
The Norwegian National Registry contains demographic data and vital status on all residents since 1965. Every resident's unique personal identification number enables linkage of data between national registries and other data sources. The Medical Birth Registry of Norway has since 1967 recorded information on all births (livebirths and stillbirths, since 1999 terminated pregnancies for fetal reasons, and since 2002 all births from 12th week gestation) on the birth notification form, including information on the mother's health, the course of the pregnancy and delivery, and the health of the newborn. 17 Oslo University Hospital's clinical registry for children with heart disease has registered all children with a heart defect admitted to Oslo University Hospital since 1992. 18 The multipurpose research project CVDNOR 19 includes information on discharge diagnoses retrieved from the electronic Patient Administrative Systems of all somatic hospitals in Norway 1994 Norway -2009 . 19 The Cause of Death Registry records contributing causes of death from death certificates. Statistics Norway provides demographic data for all residents, including educational level, occupation, income, and marital status. 20 Case ascertainment and classification of congenital heart defects Information on CHD diagnoses was retrieved from the four data sources mentioned above, as published previously, 3 where each child was assigned a cardiac phenotype with priority corresponding to the timing of presumed errors in fetal heart development 2 
Folic acid and multivitamin supplementation
Since 1999, the Medical Birth Registry of Norway has registered maternal intake of periconceptional vitamins by using five check boxes on the Birth Registry notification form from maternity units; for regular use of folic acid or multivitamins before pregnancy or during pregnancy, or for no supplement use. The embryonic cardiac development is 3-7 weeks after conception, and includes the time period when the mother likely recognises her pregnancy, with subse-392 E. Leirgul quent initiation of folic acid supplementation. We therefore decided to report risk estimates for CHD by any use of folic acid before pregnancy and/or during pregnancy, with or without multivitamin intake, referred to as periconceptional use of folic acid. Risk analyses were also performed for the other combinations of folic acid and multivitamin exposure (Table 1) . Over-the-counter folic acid supplements in Norway contained 0.4 mg folic acid and multivitamin tablets 0.0-0.2 mg folic acid during the study period 1999-2009.
Other variables
We included the following covariates as confounders of the association between folic acid intake and infant CHD risk in the multivariable model; year of birth (each year), maternal age (<20, 20-24, 25-29, 30-34 and >34 years), parity (0, 1 or ≥2 previous pregnancies), maternal education (≤10, 11-13, 14-16, ≥17 years, missing (7.8%)), marital status (married/cohabitant, single/other), maternal smoking (regular/occasional, non-smokers, did not consent to register smoking information, missing (2.8%)), and family income (quartiles of mean income of the adults in the family). In initial analyses, we evaluated maternal diabetes (pregestational or gestational) as a confounder; however, diabetes did not affect the association between folic acid and CHD, and was not included in the final adjustment model.
Study population
In the period 1999-2009, 652 977 births were registered in the Medical Birth Registry of Norway. We excluded births with chromosomal disorders (n = 2245), multiple births (n = 23 815), births from in vitro fertilisation (n = 15 791), and births with maternal epilepsy (n = 4978), in total 41 292 (6.3%) births. Among the remaining 611 685 births, we excluded 93 901 (15.4%) births without information of folic acid or multivitamin supplementation (which included the 1442 pregnancies terminated for fetal reasons), leaving 517 784 livebirths and stillbirths for analyses.
Statistical analysis
The association between maternal periconceptional folic acid supplement use and infant risk of CHD was reported as relative risk (RR); the risk of CHD among the exposed divided by the risk of CHD among the unexposed. Births without maternal intake of folic acid or multivitamin supplements were used as reference group. Crude and adjusted relative risks (aRR) with 95% confidence intervals [CI] were estimated using binomial log linear regression models with a log-link function using stata version 13 (Stata Corp., Texas, USA).
Results
Among 517 784 individuals, 6200 children had any type of CHD and 1153 had a severe CHD; the birth prevalence was 119.7 per 10 000 births and 22.3 per 10 000 births, respectively. In the period, the birth prevalence increased for total CHD until 2004, and decreased thereafter ( Figure 1 ). The prevalence for severe CHD decreased from 2005. Overall, 95 509 (18.4%) mothers had initiated folic acid supplements Table 2 , initiation of folic acid supplements before pregnancy or during pregnancy, use of multivitamins only, and no use of any supplements are shown by year of birth and maternal characteristics. Shorter education, younger age, smoking, previous births, single status, and lower family income were more frequent in mothers who did not use any folic acid or multivitamin supplements.
Maternal periconceptional use of folic acid was not associated with infant risk of severe CHD; the aRR was 0.99 [95% CI 0.86, 1.13] comparing pregnancies exposed to folic acid with non-exposed pregnancies (Table 3) Table 4 , the aRRs of the main CHD phenotypes are shown by initiation of folic acid supplementation before pregnancy (preconception) and during pregnancy (postconception). For preconceptional or postconceptional initiation of folic acid, the RRs were similar for severe defects (aRR 1.10 and aRR 0.97, respectively) and for septal defects (aRR 1.18 and aRR 1.19, respectively).
Finally, we estimated RR for CHD by various combinations of folic acid/multivitamin supplement exposures (folic acid only, folic acid and/or multivitamin supplement use before pregnancy, before and during pregnancy, or during pregnancy only) with similar results to those presented above (results not shown).
Comment
In this nationwide study of 517 784 births and 6200 children with CHD, 50% of the mothers had used folic acid supplementation in the periconceptional period. Maternal intake of folic acid supplements was not associated with infant risk of severe CHD, such as conotruncal defects, AVSD, LVOTO, and RVOTO. For septal defects, there was approximately 20% increased risk in children whose mothers had taken periconceptional folic acid supplements.
From mid-2000s there has been a decreasing prevalence of both severe and non-severe CHD in Norway, as in other European countries. 3, 7 This downward time trend has been suggested explained by the increasing intake of periconceptional folic acid and multivitamins from 1999 to 2009. 10 In Quebec, Canada, the distinct decreasing prevalence of severe CHD from 1999 coincided with implementation of folic acid fortification of grain products from 1998. 6 In Alberta, Canada, 15 there was a reduction in LVOTO (mainly CoA) in the post folic acid fortification period, but no change in the overall CHD prevalence. There was no corresponding reduction in CHD in Atlanta, Georgia, 5 despite a similar food fortification policy. Such correlating time trends of folic acid supplement use or food fortification and the birth prevalence of CHD in 11 based on telephone interviews with the mothers of 207 children with conotruncal heart defects and 481 randomly selected infants without malformations, reported reduced risk for conotruncal heart defects in children of mothers who had taken multivitamins or folic acid fortified cereals. A registrybased case-control study from the Northern Netherlands 1996-2005, 13 including 611 children with CHD, and two control groups; 2401 supposedly non-folaterelated birth defects, and 3343 pregnant women participating in previous cross-sectional studies, reported a reduced risk for CHD, mainly septal defects, in offspring of women using periconceptional folic acid supplements. In these studies, the folic acid content was similar to the presumed dose in our study (0.4 mg/d). In a case-control study from Hungary, 14 however, much higher doses were used; the estimated average dose was 5.6 mg/d. This Hungarian study compared 598 children with CHD born in 1980-1996 with 902 matched controls, 20 896 children with other malformations, and 38 151 children without birth defects, and reported a reduced risk for conotruncal heart defect in the group exposed for folic acid supplements. In a Hungarian randomised controlled trial, 12 multivitamin supplements with 0.8 mg folic acid were compared to supplements with other trace elements. There was significantly reduced risk for CHD in the group receiving vitamins with high-dose folic acid, but the numbers were small, with only 10 vs. 20 CHD cases in the exposed and unexposed group, respectively.
A possible risk reduction of CHD by intake of folic acid or multivitamin supplements is likely determined by the extent of dietary vitamin insufficiency in the population. The dietary folate intake reported in pregnant Norwegian women, around 300 μg per day, 21 could be sufficient for fetal cardiac development, as opposed to certain Chinese provinces with a high prevalence of folate deficiency, where the risk of CHD has been significantly reduced when mothers had used periconceptional folic acid supplements. 22 Alternatively, the dose of folic acid supplement in the present study, 400 μg per day, is too small to prevent cardiac malformations, although plasma folate has been found to be significantly higher in women reporting folic acid supplement use. 23 However, no risk reduction was found, even in the group with both folic acid and multivitamin supplements before and during pregnancy (approximately folic acid dose of 0.6 mg/d), suggesting the use of folic acid supplements does not prevent CHD in the Norwegian population. Changes in other risk factors may explain the recent decrease in CHD prevalence.
To our surprise, we found a significantly increased risk for both ASD and VSD if the mother had used folic acid supplements in the periconceptional period, which has not been reported previously. The increased risk of septal defects was not modified by year of birth, maternal education, or prematurity. The positive association between folic acid supplements and risk of septal defects in the present study is unlikely a chance finding but could be caused by an unknown residual confounding. A biological factor cannot be ruled out; in studies of pregnant mice, a moderate to high intake of folic acid had adverse effects on offspring cardiac development. Mikael et al. found that mice fed with a diet containing 10 times the recommended rodent folic acid intake showed an increased risk for VSDs and thinner ventricular walls than the control group. 24 The strengths of our nationwide study were the cohort design, linkage of comprehensive and compulsory registries with reliable information, and minimal loss to follow-up. Ascertainment of CHD cases through four national administrative and clinical registries enabled a virtually complete registration of both severe and minor CHD. 3 A weakness may be related to the validity of the exposure variable, maternal intake of folic acid or multivitamins, as we had no information on dose or duration of intake. However, the only folic acid tablets sold in Norway during the study period contained the recommended daily dose of 0.4 mg folic acid, and the maximum folic acid content in multivitamins was 0.2 mg. Although a large proportion of women started folic acid supplementation during pregnancy in the present study, we know from another Norwegian study in the same period that almost all folic acid users had implemented supplementation at 4 to 5 gestational week, corresponding to 2 to 3 weeks post conception (85 000 pregnancies in the Norwegian Mother and Child Cohort Study, 2001-2008), 25 which should cover most of the heart development period ranging from 3 to 7 weeks post conception. All combinations of folic acid or multivitamin intake before pregnancy or during pregnancy showed consistent findings; the association between folic acid or multivitamin supplement use and severe CHD was null, and for septal defects, there was a slightly increased risk after folic acid supplement use. Other concerns might be lack of details on additional confounders of the association between maternal supplementation and maternal/ offspring outcome, such as other dietary nutrients, or maternal pre-pregnancy weight. We did not have such information. Information on supplement use was missing in 15% of all births; these births were excluded from the study population. However, the prevalence of severe defects and septal defects were similar among births with missing folic acid information and the study population, except for the terminated pregnancies (0.2% of all births). The prevalence of CHD was increased in all terminated pregnancies (144 per 1000), but the proportion of terminated pregnancies among all births with any CHD (2.7%) or severe CHD (9.3%) was low, and amounted to a relatively small part of the births with CHD.
In conclusion, periconceptional use of folic acid or multivitamin supplements was not associated with risk of severe CHDs in infants. The association with a 20% increased risk of septal defects may be due to unknown common factors for folic acid use and CHD risk, or an adverse effect from folic acid, and warrants further investigation.
